49,765 Chemed Corporation $CHE Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH reduced its stake in shares of Chemed Corporation (NYSE:CHE) by 97.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,248 shares of the company’s stock after selling 49,765 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Chemed were worth $630,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of CHE. Monetary Solutions Ltd purchased a new stake in shares of Chemed in the 4th quarter valued at approximately $25,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Chemed during the second quarter worth $34,000. Versant Capital Management Inc raised its position in Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after purchasing an additional 75 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in Chemed in the second quarter valued at approximately $36,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Chemed by 65.3% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock worth $38,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Stock Performance

Chemed stock opened at $512.20 on Friday. The firm has a market capitalization of $6.69 billion, a P/E ratio of 24.02, a PEG ratio of 2.07 and a beta of 0.51. Chemed Corporation has a 52 week low of $365.20 and a 52 week high of $557.00. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average price of $517.57 and a 200 day moving average price of $471.11.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million for the quarter, compared to analysts’ expectations of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Equities research analysts anticipate that Chemed Corporation will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were paid a $0.70 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is an increase from Chemed’s previous quarterly dividend of $0.60. Chemed’s dividend payout ratio is presently 14.06%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CHE. Weiss Ratings upgraded shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Bank of America reiterated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer boosted their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. UBS Group started coverage on shares of Chemed in a research report on Friday, September 25th. They set a “buy” rating and a $650.00 target price on the stock. Finally, Royal Bank Of Canada lifted their price objective on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Chemed currently has an average rating of “Hold” and a consensus target price of $554.60.

Insiders Place Their Bets

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the sale, the chief executive officer directly owned 66,418 shares in the company, valued at approximately $34,102,322.10. This trade represents a 2.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Spencer S. Lee sold 1,000 shares of Chemed stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $541.04, for a total transaction of $541,040.00. Following the sale, the executive vice president owned 13,912 shares in the company, valued at $7,526,948.48. This represents a 6.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,190 shares of company stock worth $4,833,160 over the last ninety days. 3.33% of the stock is owned by company insiders.

Chemed Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.